0000899243-21-003669.txt : 20210128 0000899243-21-003669.hdr.sgml : 20210128 20210128193925 ACCESSION NUMBER: 0000899243-21-003669 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210126 FILED AS OF DATE: 20210128 DATE AS OF CHANGE: 20210128 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rohlen Douglas CENTRAL INDEX KEY: 0001306344 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38533 FILM NUMBER: 21567344 MAIL ADDRESS: STREET 1: 3600 HOLLY LANE NORTH, SUITE 40 CITY: PLYMOUTH STATE: MN ZIP: 55447 FORMER NAME: FORMER CONFORMED NAME: Rohlen Duke DATE OF NAME CHANGE: 20041019 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Eidos Therapeutics, Inc. CENTRAL INDEX KEY: 0001731831 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 463733671 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 101 MONTGOMERY STREET, SUITE 2550 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 650-391-9740 MAIL ADDRESS: STREET 1: 101 MONTGOMERY STREET, SUITE 2550 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-01-26 1 0001731831 Eidos Therapeutics, Inc. EIDX 0001306344 Rohlen Douglas C/O EIDOS THERAPEUTICS, INC. 101 MONTGOMERY STREET, SUITE 2000 SAN FRANCISCO CA 94104 1 0 0 0 Stock Option (Right to Buy) 41.42 2021-01-26 4 D 0 21447 D 2030-08-05 Common Stock 21447 0 D Restricted Stock Units 0.00 2021-01-26 4 D 0 4526 D Common Stock 4526 0 D Pursuant to the terms of the Agreement and Plan of Merger dated October 5, 2020 (the "Merger Agreement"), by and among the Issuer, BridgeBio Pharma, Inc. ("Parent"), Globe Merger Sub 1, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), and Globe Merger Sub II, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub II"), Merger Sub was merged with and into the Issuer, with the Issuer continuing as the surviving corporation and immediately thereafter, the Issuer was merged with and into Merger Sub II, with Merger Sub II continuing as the surviving corporation, effective as of January 26, 2021 (the "Effective Time"). (Continued From Footnote 1) The option vests in three annual installments after August 6, 2020. At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time. Pursuant to the Merger Agreement, each restricted stock unit that was outstanding immediately prior to the Effective Time was cancelled and automatically converted into 1.85 shares of Parent common stock. /s/ Franco Valle, Attorney-in-Fact 2021-01-28